Bayer Sees Positive Results in Study for Asundexian as Stroke Treatment
The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study.
Bayer reports positive results for blood thinner after 2023 setback
German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
Bayer BAYRY obtained European Commission approval for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause or caused by adjuvant endocrine therapy (AET) related to breast cancer.
Why Bayer Aktiengesellschaft (BAYRY) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bayer Aktiengesellschaft (BAYRY) Q3 2025 Earnings Call Transcript
Bayer Aktiengesellschaft (OTCPK:BAYRY) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Jost Reinhard - Senior VP & Head of Investor Relations William Anderson - Chairman of the Management Board & CEO Wolfgang Nickl - CFO & Member of Management Board Stefan Oelrich - Head of the Pharmaceuticals Division & Member of the Board of Management Dave Tomasi - President of Bayer and Head of Comm. Ops. of Consumer Health, NA Rodrigo Santos - Member of Management Board & President of the Crop Science Division Conference Call Participants Thibault Boutherin - Morgan Stanley, Research Division Sachin Jain - BofA Securities, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Laurent Favre - BNP Paribas, Research Division Charles Pitman - Barclays Bank PLC, Research Division Christian Faitz - Kepler Cheuvreux, Research Division Florent Cespedes - Sanford C.
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.
Bayer Posts Net Loss on Litigation Hit
Bayer's net loss narrowed in the third quarter but additional litigation provisions weighed on its crop-science business.
Bayer's third-quarter adjusted profit beats market view
Bayer said on Wednesday that third-quarter adjusted operating income gained 20.8%, citing gains at the Crop Science division and reconciliation effects in accounting.
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Why Bayer's Worst Years Might Be The Start Of Its Comeback
Bayer Aktiengesellschaft remains deeply undervalued despite ongoing business struggles and litigation headwinds, with significant upside potential if challenges are resolved. Bayer's Q2 '25 results were mediocre, but the company raised 2025 guidance and is making progress on litigation settlements, aiming for containment by the end of 2026. The turnaround strategy includes workforce reductions, deleveraging, and new product launches, but core segments still face sales and profit pressures, especially in Crop Science and Pharma.
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
Focus: Parkinson's disease at forefront of Bayer bet on cell and gene therapies
Bayer's pioneering cell and gene therapies for Parkinson's disease are at the forefront of an exciting but risky test of CEO Bill Anderson's development credentials as patent expiries on blockbuster drugs threaten the group's long-term growth projects.
